What did we learn from new oral anticoagulant treatment?
- 31 October 2012
- journal article
- review article
- Published by Elsevier in Thrombosis Research
- Vol. 130 (Suppl 1) , S41-S43
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- New AnticoagulantsCirculation, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialThe Lancet, 2009
- Vitamin K-dependent Proteins, Warfarin, and Vascular CalcificationClinical Journal of the American Society of Nephrology, 2008
- The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in HumansDrug Metabolism and Disposition, 2008
- New anticoagulantsJournal of Thrombosis and Haemostasis, 2005
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990